5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-β1 induced non-canonical signaling pathways including STAT3 : implications for fibrotic diseases like scleroderma.
Saurabh ChaturvediDurga Prasanna MisraNarayan PrasadKailash RastogiHarshit SinghMohit Kumar RaiVikas AgarwalPublished in: International journal of rheumatic diseases (2018)
Terguride and SB204741 reduce pro-fibrotic potential of HADF cells and suppress TGF-β1-mediated non-canonical pathways, ERK1/2 and STAT3 which have been implicated in the regulation of pro-fibrotic genes and in the development of fibrosis. Taken together, our data suggest that 5-HT inhibitors might reduce fibrosis via suppression of TGF-beta1-mediated non-canonical signaling pathways. These observations have important therapeutic implications for fibrotic disorders like scleroderma.
Keyphrases
- systemic sclerosis
- signaling pathway
- idiopathic pulmonary fibrosis
- interstitial lung disease
- transforming growth factor
- induced apoptosis
- cell proliferation
- pi k akt
- anti inflammatory
- endothelial cells
- epithelial mesenchymal transition
- cell cycle arrest
- genome wide
- electronic health record
- gene expression
- high glucose
- liver fibrosis
- extracellular matrix